The sale of a significant portfolio segment like the medicated feed additive to Phibro Animal Health for a substantial amount of $350 million is viewed positively by the market, reflecting optimism in Zoetis's strategic decisions and potential for future growth or reallocation of resources. This transaction indicates a strong strategic move that could enhance Zoetis's financial flexibility and focus on more profitable areas, leading to the positive reaction in its stock price.